Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eli Lilly, BioMS in MBP8298 deal

BioMS (TSX:MS) granted LLY an exclusive, worldwide license to

Read the full 94 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE